Back to results
US 2019/0054085 A1Published application
Composition and method for treatment of depression and psychosis in humans
AssigneeGlytech, Inc.
InventorDaniel C. Javitt
Life of this patent
Estimating the term…
Abstract
This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.
Claims20
A method for treatment of depression or suicidal ideation comprising:
- administering to a subject in need thereof
- a first agent comprising D-cycloserine at an antagonist dose;
- and
- a second agent comprising an anti-depressant or atypical antipsychotic, wherein the D-cycloserine is administered at a dose of ≥500 to ≤1000 mg/kg, and is formulated to produce an average plasma level in the subject of greater than 25 μg/mL, thereby treating the depression or suicide ideation.
1 more element
Dependencies are inferred from the claim text.